Organ-Chip Expansion Emulate is rapidly expanding its Organ-Chip platform with new Liver-Chip BioKit and Brain-Chip R1 launches, creating cross-sell opportunities to existing customers seeking additional organ models and integrated perfusion capabilities.

Pharma Partnerships Recent collaborations and FDA ISTAND validation position Emulate as a trusted partner for safety and efficacy testing, suggesting upsell potential in larger pharma and biotech accounts aiming to accelerate IND submissions and reduce animal testing.

Automation Advantage The AVA Emulation System enables high-throughput culture and imaging of up to 96 Organ-Chip samples, offering a compelling value proposition for CROs and pharmaceutical teams pursuing scalable, end-to-end organ modeling workflows.

Academic & Vet Alignment Strategic partnerships like with the Royal Veterinary College indicate opportunities to tailor organ models for veterinary research and comparative biology, broadening potential client segments and grant-driven sales.

Financial Readiness With substantial funding and revenue in the mid tens of millions range and a robust product roadmap, Emulate has the financial capacity to invest in larger pilot programs, long-term contracts, and channel partnerships to accelerate deployments.